Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.ZIOP · Entity 8339 | Director | September 02, 2021 | September 03, 2021 |
| Obsidian Therapeutics, Inc.OBX · Entity 4898 | Director | August 03, 2026 | August 05, 2026 |
| Vericel CorpVCEL · Entity 4481 | Director | April 29, 2026 | May 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date September 02, 2021 · Filed September 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 145,889 |
Reported balance
After 2021-09-02 transaction · row 1
1 source rowRow 1 · 2021-09-02 · Purchase · Acquired 23,770 · Balance 145,889 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.74 to $1.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.74 to $1.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Obsidian Therapeutics, Inc.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2036-08-02 | Direct | 37,653 |
Reported balance
After 2026-08-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-03 · Grant · Acquired 37,653 · Balance 37,653 F1: The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.
Vericel Corp
Report date April 29, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,050 |
Reported balance
After 2026-04-29 transaction · row 1
1 source rowRow 1 · 2026-04-29 · Exercise / conversion · Acquired 3,200 · Balance 35,050 F1: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 30, 2025. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-29 · Exercise / conversion · Acquired 3,200 · Balance 0 F2: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3: These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025. F4: No expiration date for this type of award. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 3,200 |
Reported balance
After 2026-04-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-29 · Grant · Acquired 3,200 · Balance 3,200 F2: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6: These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders following April 29, 2026. F4: No expiration date for this type of award. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.43 · Expires 2036-04-29 | Direct | 8,000 |
Reported balance
After 2026-04-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-29 · Grant · Acquired 8,000 · Balance 8,000 F5: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 30, 2025.
F2: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
F3: These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025.
F4: No expiration date for this type of award.
F5: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company.
F6: These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders following April 29, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 5, 2026 20:06 UTC | Obsidian Therapeutics, Inc. OBX · Entity 4898 | GrantStock Option (Right to Buy) · Derivative | 37,653 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001193125-26-335055 · ownership.xml · derivative · entry 1 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,653 Underlying: Common Stock · 37,653 shares Expires 2036-08-02 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the Issuer's annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date. Read SEC document |
| April 29, 2026 Filed May 1, 2026 20:06 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-018543 · form4.xml · derivative · entry 4 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,200 Underlying: Common Stock · 3,200 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders following April 29, 2026. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 29, 2026 Filed May 1, 2026 20:06 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0001140361-26-018543 · form4.xml · derivative · entry 3 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2036-04-29 F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 29, 2026 Filed May 1, 2026 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-018543 · form4.xml · derivative · entry 2 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 29, 2026 Filed May 1, 2026 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 3,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-018543 · form4.xml · nonDerivative · entry 1 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 30, 2025. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001140361-26-011091 · form4.xml · derivative · entry 3 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 15,000 shares, were originally granted on May 4, 2016, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company. F3 · derivative.expiration_date: These options, which were awarded on May 4, 2016, would otherwise expire and become forfeitable on May 4, 2026. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 20:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 15,000 | $32.41 | $486,150.00 |
DisclosureSEC source: 0001140361-26-011091 · form4.xml · nonDerivative · entry 2 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,850 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 15,000 | $2.76 | $41,400.00 |
DisclosureSEC source: 0001140361-26-011091 · form4.xml · nonDerivative · entry 1 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:07 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-017118 · form4.xml · derivative · entry 4 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,200 Underlying: Common Stock · 3,200 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:07 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $38.02 | $0.00 |
DisclosureSEC source: 0001140361-25-017118 · form4.xml · derivative · entry 3 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2035-04-30 F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:07 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-017118 · form4.xml · derivative · entry 2 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of May 1, 2025, or the date of the first Annual Meeting of Stockholders following May 1, 2024. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 30, 2025 Filed May 2, 2025 20:07 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 3,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-25-017118 · form4.xml · nonDerivative · entry 1 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on May 1, 2024. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001140361-25-007181 · form4.xml · derivative · entry 3 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 15,000 shares, were originally granted on March 20, 2015, with 624 shares becoming exercisable on the grant date, 312 shares becoming exercisable on March 31, 2015, and the remainder becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from April 30, 2015 through December 31, 2017. F3 · derivative.expiration_date: These options, which were awarded on March 20, 2015, would otherwise expire and become forfeitable on March 20, 2025. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | SaleCommon Stock | 9,000 | $49.53 | $445,770.00 |
DisclosureSEC source: 0001140361-25-007181 · form4.xml · nonDerivative · entry 2 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,650 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2024. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 9,000 | $3.74 | $33,660.00 |
DisclosureSEC source: 0001140361-25-007181 · form4.xml · nonDerivative · entry 1 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 17, 2024 Filed Oct 21, 2024 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001140361-24-043798 · form4.xml · derivative · entry 4 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options, representing the right to purchase 15,000 shares, were originally granted on March 20, 2015, with 624 shares becoming exercisable on the grant date, 312 shares becoming exercisable on March 31, 2015, and the remainder becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from April 30, 2015 through December 31, 2017. F3 · derivative.expiration_date: These options, which were awarded on March 20, 2015, would otherwise expire and become forfeitable on March 20, 2025. Read SEC document |
| October 17, 2024 Filed Oct 21, 2024 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001140361-24-043798 · form4.xml · derivative · entry 3 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 4,000 shares, became exercisable in three installments, contingent upon continued service to the Company, with the first vesting date on March 20, 2015, which was the date on which the option was granted, and the final vesting date on May 1, 2015. F3 · derivative.expiration_date: These options, which were awarded on March 20, 2015, would otherwise expire and become forfeitable on March 20, 2025. Read SEC document |
| October 17, 2024 Filed Oct 21, 2024 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 6,000 | $3.74 | $22,440.00 |
DisclosureSEC source: 0001140361-24-043798 · form4.xml · nonDerivative · entry 2 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold these shares at this time. Read SEC document |
| October 17, 2024 Filed Oct 21, 2024 20:05 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 4,000 | $3.74 | $14,960.00 |
DisclosureSEC source: 0001140361-24-043798 · form4.xml · nonDerivative · entry 1 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold these shares at this time. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:06 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-024331 · form4.xml · derivative · entry 4 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,200 Underlying: Common Stock · 3,200 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of May 1, 2025, or the date of the first Annual Meeting of Stockholders following May 1, 2024. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:06 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $47.08 | $0.00 |
DisclosureSEC source: 0001140361-24-024331 · form4.xml · derivative · entry 3 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2034-05-01 F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-024331 · form4.xml · derivative · entry 2 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of May 3, 2024, or the date of the first Annual Meeting of Stockholders following May 3, 2023. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:06 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 3,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-024331 · form4.xml · nonDerivative · entry 1 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on May 3, 2023. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:05 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-023196 · form4.xml · derivative · entry 2 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,200 Underlying: Common Stock · 3,200 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of May 3, 2024 or the date of the first Annual Meeting of Stockholders following May 3, 2023. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:05 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $32.12 | $0.00 |
DisclosureSEC source: 0001140361-23-023196 · form4.xml · derivative · entry 1 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2033-05-03 F1 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 20:04 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-021498 · form4.xml · derivative · entry 2 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 27, 2023 or the date of the first Annual Meeting of Stockholders following April 27, 2022. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 20:04 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 2,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-021498 · form4.xml · nonDerivative · entry 1 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,450 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 27, 2022. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:03 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $31.99 | $0.00 |
DisclosureSEC source: 0001593968-22-000888 · primary_01.xml · derivative · entry 4 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2032-04-27 F6 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:03 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000888 · primary_01.xml · derivative · entry 3 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600 Underlying: Common Stock · 2,600 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F5 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 27, 2023 or the date of the first Annual Meeting of Stockholders following April 27, 2022. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:03 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-22-000888 · primary_01.xml · derivative · entry 2 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 28, 2022 or the date of the first Annual Meeting of Stockholders following April 28, 2021. The first Annual Meeting of Stockholders occurred on April 27, 2022. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 20:03 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 2,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593968-22-000888 · primary_01.xml · nonDerivative · entry 1 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 28, 2021. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 21:25 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | PurchaseCommon Stock | 23,770 | $1.76 | $41,835.20 |
DisclosureSEC source: 0001209191-21-054829 · doc4.xml · nonDerivative · entry 1 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,889 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.74 to $1.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:10 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001593968-21-001389 · primary_01.xml · derivative · entry 6 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2024-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options, representing the right to purchase a total of 3,000 shares, became exercisable in equal monthly installments over one year, beginning on May 7, 2014, contingent upon continued service to the Company. Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:10 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 2,250 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001593968-21-001389 · primary_01.xml · derivative · entry 5 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,250 shares Expires 2023-08-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase a total of 2,250 shares, became exercisable in equal monthly installments over nine months, beginning on August 23, 2013, contingent upon continued service to the Company. Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:10 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001593968-21-001389 · primary_01.xml · derivative · entry 4 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2023-08-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 1,500 shares, became exercisable in equal monthly installments over one year, beginning on August 23, 2013, contingent upon continued service to the Company. Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:10 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 2,250 | $6.00 | $13,500.00 |
DisclosureSEC source: 0001593968-21-001389 · primary_01.xml · nonDerivative · entry 3 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold these shares at this time. Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:10 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 3,000 | $4.12 | $12,360.00 |
DisclosureSEC source: 0001593968-21-001389 · primary_01.xml · nonDerivative · entry 2 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold these shares at this time. Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:10 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 1,500 | $6.00 | $9,000.00 |
DisclosureSEC source: 0001593968-21-001389 · primary_01.xml · nonDerivative · entry 1 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold these shares at this time. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:07 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-001209 · primary_01.xml · derivative · entry 4 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600 Underlying: Common Stock · 2,600 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 28, 2022 or the date of the first Annual Meeting of Stockholders following April 28, 2021. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:07 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $63.22 | $0.00 |
DisclosureSEC source: 0001593968-21-001209 · primary_01.xml · derivative · entry 3 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2031-04-28 F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:07 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-001209 · primary_01.xml · derivative · entry 2 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 29, 2021 or the date of the first Annual Meeting of Stockholders following April 29, 2020. The first Annual Meeting of Stockholders occurred on April 28, 2021. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:07 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593968-21-001209 · primary_01.xml · nonDerivative · entry 1 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units granted to the Reporting Person on April 29, 2020. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:28 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 675,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-018629 · doc4.xml · derivative · entry 2 Hagen Heidi · CIK 0001585084 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675,000 Underlying: Common Stock · 675,000 shares Expires 2031-03-04 F2 · derivative.exercise_date: 1/12th of the shares underlying this option will vest in equal monthly installments commencing one month after 3/4/2021. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:28 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 90,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018629 · doc4.xml · nonDerivative · entry 1 Hagen Heidi · CIK 0001585084 · Director · Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,119 F1 · shares: The shares will fully vest on 3/4/2022. Read SEC document |
| April 29, 2020 Filed May 1, 2020 20:14 UTC | Vericel Corp VCEL · Entity 4481 | GrantStock Option (right to buy) · Derivative | 13,125 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001593968-20-001088 · primary_01.xml · derivative · entry 4 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,125 Underlying: Common Stock · 13,125 shares Expires 2030-04-29 F6 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 29, 2020 Filed May 1, 2020 20:14 UTC | Vericel Corp VCEL · Entity 4481 | GrantRestricted Stock Unit · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-20-001088 · primary_01.xml · derivative · entry 3 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Underlying: Common Stock · 1,750 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F5 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 29, 2021 or the date of the first Annual Meeting of Stockholders following April 29, 2020. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 29, 2020 Filed May 1, 2020 20:14 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionRestricted Stock Unit · Derivative | 1,750 | $14.56 | $25,480.00 |
DisclosureSEC source: 0001593968-20-001088 · primary_01.xml · derivative · entry 2 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of May 1, 2020 or the date of the first Annual Meeting of Stockholders following May 1, 2019. The first Annual Meeting of Stockholders occurred on April 29, 2020. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 29, 2020 Filed May 1, 2020 20:14 UTC | Vericel Corp VCEL · Entity 4481 | Exercise / conversionCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-20-001088 · primary_01.xml · nonDerivative · entry 1 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units granted to the Reporting Person on May 1, 2019. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 22:08 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 31,780 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-001175 · doc4.xml · nonDerivative · entry 1 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,119 F1 · shares: 31,780 shares vest on 12/31/2020. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 20:36 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantStock Option (right to buy) · Derivative | 93,922 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001209191-19-037401 · doc4.xml · derivative · entry 1 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,922 Underlying: Common Stock · 93,922 shares Expires 2029-06-12 F1 · derivative.exercise_date: 93,922 shares vest on 6/13/2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.